204 related articles for article (PubMed ID: 23126027)
21. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
[TBL] [Abstract][Full Text] [Related]
22. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
[TBL] [Abstract][Full Text] [Related]
23. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
[TBL] [Abstract][Full Text] [Related]
24. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
25. Infrequent hypermethylation of WIF-1 promoter in BCR/ABL-negative myeloproliferative disorders.
Suzuki R; Onizuka M; Kojima M; Shimada M; Tsuboi K; Ogawa Y; Kawada H; Ando K
Tokai J Exp Clin Med; 2007 Dec; 32(4):131-5. PubMed ID: 21318952
[TBL] [Abstract][Full Text] [Related]
26. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
[TBL] [Abstract][Full Text] [Related]
27. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders.
Speletas M; Katodritou E; Daiou C; Mandala E; Papadakis E; Kioumi A; Ritis K; Korantzis I
Leuk Res; 2007 Aug; 31(8):1053-62. PubMed ID: 17045648
[TBL] [Abstract][Full Text] [Related]
28. Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods.
Cankovic M; Whiteley L; Hawley RC; Zarbo RJ; Chitale D
Am J Clin Pathol; 2009 Nov; 132(5):713-21. PubMed ID: 19846812
[TBL] [Abstract][Full Text] [Related]
29. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN).
Kodali S; Chen C; Rathnasabapathy C; Wang JC
Leuk Res; 2009 Dec; 33(12):e236-9. PubMed ID: 19625083
[TBL] [Abstract][Full Text] [Related]
30. Analysis of JAK2(V617F) mutation in Chinese patients with myeloproliferative disorders.
Chen S; Fei H; Zhang R; Xue Y; Pan J; Wu Y; Ceng J
Am J Hematol; 2007 Jun; 82(6):458-9. PubMed ID: 17266061
[TBL] [Abstract][Full Text] [Related]
31. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
32. Proteolytic matrix metallopeptidases and inhibitors in BCR-ABL1-negative myeloproliferative neoplasms: correlation with JAK2 mutation status.
Vadikolia CM; Tsatalas C; Anagnostopoulos K; Trypsianis G; Pantelidou D; Bazdiara I; Anastasiadis A; Spanoudakis E; Kotsianidis I; Margaritis D; Kortsaris A; Bourikas G
Acta Haematol; 2011; 126(1):54-62. PubMed ID: 21474922
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations.
Lakey MA; Pardanani A; Hoyer JD; Nguyen PL; Lasho TL; Tefferi A; Hanson CA
Am J Clin Pathol; 2010 Jun; 133(6):942-8. PubMed ID: 20472853
[TBL] [Abstract][Full Text] [Related]
34. [Investigation of Laboratory and Clinical Feature in the Patients with Myeloproliferative Neoplasm Co-expression of BCR-ABL1 and JAK2 V617F].
Yuan XG; Wan RT; Zhao XW; Yang XZ; Xiao J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1236-1241. PubMed ID: 34362508
[TBL] [Abstract][Full Text] [Related]
35. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
[TBL] [Abstract][Full Text] [Related]
36. Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F.
Gibson SE; Schade AE; Szpurka H; Bak B; Maciejewski JP; Hsi ED
Hum Pathol; 2008 Jul; 39(7):1111-4. PubMed ID: 18479730
[TBL] [Abstract][Full Text] [Related]
37. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
38. Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.
Tatic A; Vasilică M; Coliţă A; Vasilache D; Dobrea C; Jardan C; Găman AM; Crişan AM; Coliţă D; Coriu D
Rom J Morphol Embryol; 2013; 54(4):1177-82. PubMed ID: 24399021
[TBL] [Abstract][Full Text] [Related]
39. Anti-apoptotic pathways in bone marrow and megakaryocytes in myeloproliferative neoplasia.
Koopmans SM; Schouten HC; van Marion AM
Pathobiology; 2014; 81(2):60-8. PubMed ID: 24280934
[TBL] [Abstract][Full Text] [Related]
40. A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease.
Roug AS; Nyvold CG; Juhl-Christensen C; Christensen M; Schnittger S; Hokland P
Eur J Haematol; 2011 Nov; 87(5):461-3. PubMed ID: 21689158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
